130 results
Page 3 of 7
S-4
EX-10.9
qcitl 8m4bk4p7y4gtoo
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.15
g4jc ms0ogbjvqnq2
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
zaf2jum3 ypy
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-2.2
g0flxlxaom9 p2y
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-2.3
ky5xkr
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.19
047ia6b ggd
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.14
3a2usl
11 May 23
Registration of securities issued in business combination transactions
9:09am
425
31c3bxxk8vf7fvt
18 Apr 23
Business combination disclosure
5:12pm
6-K
EX-99.3
hg6bfb89axtgcc
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.1
aey17lb
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.2
heyfliwjam67ho
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.1
rgwvcb
1 Sep 22
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
5:16pm
6-K
39rq5ga 433y
1 Sep 22
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
5:16pm
6-K
EX-99.3
fyy f5wtq
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
EX-99.1
f44yvw8iqv
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
EX-99.1
za3oyyrympge
2 Aug 22
VBL Therapeutics Announces Workforce Reduction
8:32am
6-K
oh2uuom
2 Aug 22
VBL Therapeutics Announces Workforce Reduction
8:32am
6-K
EX-99.1
o71c4m8cw7y9m ow2a0
19 Jul 22
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
4:09pm
6-K
EX-99.2
kvd in0fuaxfm1he
2 Jun 22
Notice of Annual General Meeting of Shareholders
5:00pm
6-K
EX-99.1
aokkp03r5ww
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am